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Abstract: 
Selective depletion (SD) of alloreactive T cells from allogeneic hematopoeitic stem cell 
transplants (aHSCT) to prevent graft-versus-host disease (GVHD) without compromising 
immune reconstitution and anti-tumour responses remains a challenge. Here, we demonstrate a 
novel SD strategy whereby alloreacting T cells are efficiently deleted ex vivo with adenosine. SD 
was achieved in HLA mismatched co-cultures by multiple exposures to 2mM adenosine over 
seven days. Adenosine depleted greater than to 90% of alloproliferating T cells in mismatched, 
haploidentical, and matched sibling pairs while conserving response to 3rd party antigens. 
Alloreactive CD4 and CD8 T cells were targeted for depletion while NK and B cells were 
preserved. Our novel approach also preserved non-alloreactive naïve, central and effector 
memory T cell subsets, Tregs, and notably preserved T cell responses against DNA viruses that 
contribute to transplant related mortality after aHSCT. Additionally, T cells recognizing 
leukemia-associated antigens were efficiently generated in vitro from the cell product post SD. 
This study is the first to demonstrate that adenosine depletion of alloactivated T cells maintains a 
complete immune cell profile and recall viral responses. Expansion of tumor antigen specific 
subsets post-depletion opens the possibility of generating T cell products capable of graft-versus-
tumor responses without causing GVHD. 
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Introduction 
 
The focus of any strategy to optimize the outcome of allogeneic stem cell transplant 
(SCT) is to manipulate the incoming donor T cell repertoire so as to prevent graft versus host 
disease (GVHD) provoked by major and minor recipient histocompatibility antigens (HLA) 
while preserving cells capable of restoring cellular immunity, especially against microbial 
infections, common viruses, and tumors in the case of transplants for malignant disease. Current 
haploidentical transplant approaches to prevent GVHD, which preserve at least some protective 
immunity against viral reactivation and disease recurrence, range from T cell depletion,1 
intensive post-transplant immunosuppression,2 or in vivo elimination of alloreacting T cells early 
post graft using high dose cyclophosphamide.3,4 An important contribution to the successful 
suppression of GVHD is the preservation of regulatory T cells (Tregs), which have a selective 
advantage in suppressing GVHD while permitting immune recovery.5-7 An alternative approach 
is the ex vivo selective depletion (SD) of T cells responsible for the donor’s alloresponse against 
recipient mononuclear cells.8  In this approach the donor lymphocytes are cocultured with either 
irradiated lymphocytes from the recipient in a mixed lymphocyte reaction (MLR) or other 
irradiated recipient mononuclear cells in a modified MLR (mMLR). Alloactivated donor T cells 
can then be eliminated or rendered non-functional by antibodies or immunotoxins targeting 
activation antigens (CD25, CD69), or by photodepletion of activated T cells.9 Off-target 
depletion of the crucial CD25+ Treg population along with poor depletion efficacy, possibly due 
to down-regulation of targeted antigens, has hampered the success of immune-magnetic and 
immunotoxin approaches. Photodepletion with a TH9402-based dye failed to improve outcomes 
in HLA matched sibling transplants but has shown promise in haploidentical transplants.10-12 An 
effective, immune modulating strategy for SD which conserves Tregs and can be consistently 
and easily reproduced in clinical scale has not yet been achieved. 
 Here, we present a novel strategy for allodepletion employing ex vivo treatment of 
alloreacting donor T cells with adenosine. Adenosine is a purine nucleoside FDA-approved for 
treatment of supraventricular tachycardia. In physiological conditions adenosine plays an integral 
role in thymic function and peripheral tissue homeostasis. In hypoxic and inflammatory 
environments, such as the tumor microenvironment, adenosine regulates inflammation, inducing 
tolerance and immune suppression.13-15 Here we exploited the immune regulatory effects of 
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adenosine for prevention of GVHD and demonstrate that pharmacological doses of adenosine 
efficiently deplete activated alloreactive T cells from mismatched or haplo identical donor 
lymphocyte populations while retaining desirable cell subsets essential for normal immune 
reconstitution.  
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Results 
 
Adenosine selectively depletes allo-activated T cells 
Healthy donor lymphocytes were stimulated with randomly mismatched DC in mMLR 
assay. T cells were analyzed for CD25 expression to measure activation and CFSE dilution to 
measure proliferation. Adenosine, a short-lived biological agent, was added at 48 hour intervals 
(days 1, 3, and 5) in concentrations varying from 10uM to 1mM. Suppression of CD25 
expression was observed at the highest 1mM concentration of adenosine (Fig. 1a). In subsequent 
experiments 2mM adenosine was used to ensure suppression of activation and proliferation. 
Multiple treatments of adenosine over a five day period were necessary to achieve sustained 
suppression of T cell proliferation (Fig. 1b). A single early treatment on the second day of 
culture suppressed activation, but T cell proliferation was noticed on days 8-10 indicating the 
presence of a residual group of late-responding cells. A single late treatment (day 5) only 
eliminated about half of proliferating cells. Combining the early and late treatments by 
administering adenosine on days 1, 2, and 5 after establishing mMLR successfully suppressed 
proliferation up to 5 days after the final treatment. 
To explore cytotoxic effects of adenosine on activated T cells, lymphocytes were 
stimulated with anti-CD3/CD28 beads and treated with adenosine (Fig. 1c). Vivid viability 
staining revealed major reduction in viable lymphocytes and increased cell debris in adenosine 
treated samples. Direct induction of apoptosis was assessed by culturing lymphocytes from four 
healthy donors either alone, with a mix of DC from three mismatched donors, or anti-CD3/CD28 
beads. After 72 hours, half of the cultures were incubated with 2mM adenosine for 5 minutes 
before staining with Annexin V and PI. Paired T test statistical analysis showed a significant 
increase in PI+AnnexinV+ cells in both allo-stimulated and bead-stimulated cultures (P=0.04, 
P=0.02) but no significant change in this population for unstimulated lymphocytes (P=0.6, Table 
S1). These results suggest that adenosine is toxic towards and capable of depleting T cells 
activated by allo- or anti-CD3/CD28 stimulation. The lack of significant induction of apoptosis 
in unstimulated T cells suggests that this depletion is selective to activated cells, but does not 
definitively discount that some non-activated, non-proliferating population of cells may also be 
affected. 
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 From these experiments, a standard SD protocol was devised in which cultures 
established on day 0 were treated with 2mM adenosine as a 2X solution on days 1, 2, and 5. In 
12 consecutive experiments the allodepleted product, collected on day 7, comprised 54±0.09% of 
initial lymphocytes with a viability of 91.32 ± 2.4%. In comparison, lymphocytes cultured 
without manipulation for 7 days comprised 42.3±11.2% of initial cells with a viability of 89.3 ± 
3.7% (N=6). 
 
Adenosine inhibits T cell response against allostimulating DCs while retaining third party 
responses and proliferative capacity 
The ability of adenosine to functionally deplete ‘donor’ alloreactive T cells was assessed 
by restimulation of adenosine allodepleted lymphocytes against DC stimulators from the original 
HLA-mismatched ‘recipient’. Elimination of alloreactive cells was identified as the absence of 
proliferation on rechallenge with the original “recipient” cells. A comparison of the proliferation 
of freshly thawed lymphocytes and adenosine allodepleted lymphocytes stimulated by DC in a 
representative donor-recipient pair is shown in Fig. 2a. The frequency of proliferating donor-
derived responder T cells fell from 70.9% to 4.2% after depletion. 
Selectivity of allodepletion was assessed in side-by-side proliferation challenge of 
responder T lymphocytes from adenosine-depleted cocultures and unmanipulated control 
cultures against a panel of stimulators. To account for possible confounding effects of prolonged 
culture, unstimulated lymphocytes cultured alone for 7 days were used as unmanipulated 
controls. Stimulators employed in this assay were autologous DC to measure background 
proliferation, recipient DC to measure depletion, a mix of DCs from 3 unrelated donors to 
measure third party mMLR response, and anti-CD3/CD28 beads to measure maximum 
proliferative capacity. Proliferation of responder cells was assessed by dilution of CFSE dye 
measured by flow cytometry after 5 day coculture period with stimulators. 
Pooled data from 5 experiments (Figs. 2b,c) show that adenosine treatment achieved 
significant depletion of proliferating alloreactive cells in mMLR. As shown in Fig. 2c, 0.4 ± 
0.4% T cells from allodepleted mMLR proliferated in secondary response against recipient DC, 
compared to the 31.3 ± 3.1% primary response of unmanipulated control cultures and indicates a 
significant depletion of 98.7% of alloproliferative response (P=0.000015). Donor T cells from 
both adenosine treated and control cultures elicited a strong allo-response against 3rd party DCs 
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(25.9 ± 5.3% and 49.3 ± 5.3%, respectively), but this response was significantly decreased in the 
depleted cultures (P=0.014, *). Notably, both cultures proliferated robustly in response to anti-
CD3/CD28 stimulation, 62.9 ± 8.7% for adenosine depleted and 59.6 ± 14.0% for the untreated 
control, suggesting that remaining T cells were viable and able to proliferate after adenosine 
treatment.  
 
Impact of adenosine on viability and individual lymphocyte subsets 
Fig. 3a shows that adenosine-mediated cellular depletion was restricted to the T 
lymphocyte compartment; the frequency of B and NK cell populations increased in adenosine 
treated cultures (NK: 8.72 ± 1.17%, B: 8.08 ± 1.33%, N=12) compared to untreated control 
cultures (NK: 4.82 ± 1.09%, B: 6.06 ± 1.78%, N=6). Although adenosine appeared to primarily 
affect the CD4+ Th subset (Fig. 3a), as evidenced by the slight decrease (51.23 ± 3.35%, N=18) 
compared to unstimulated control cultures (58.33 ± 5.15%, N=6), this effect was not statistically 
significant. 
Phenotypic analysis of the T cell subsets revealed no significant changes in the 
distribution of T cells among naïve, EM, CM, and effector compartments in adenosine treated 
mMLR cocultures compared to the phenotype of unstimulated T cells (Figs. 3c,d). However, we 
found a significant reduction in the frequency of naïve T cells with a concurrent increase in CM 
and to a lesser extent EM compartments in untreated, alloreacting mMLR cultures (Figs. 3c,d). 
These results corroborate previous findings that alloreactive T cells are mainly recruited from the 
naïve subset.16 
 
Regulatory T cells are preserved in adenosine treated cultures 
Donor regulatory lymphocytes, in particular Tregs, are essential for protection against 
GVHD in patients following cell transfer. In 6/6 donors, CD4+CD25+FOXP3+ Tregs were 
identified after SD with adenosine (Fig. 4a,b) and 5 of 6 donors showed an increased frequency 
over unstimulated lymphocyte controls. Although the frequency of Tregs varied in untreated 
mMLR according to the individual stimulator DC, the frequency of Tregs persisting in cultures 
treated with adenosine was mostly dependent on the responder T cells. Data shown in Fig. 4b 
indicate that the relative frequency of Treg populations within CD3+CD4+ subset in mMLR 
cultures treated with adenosine (2.20 ± 0.40%, N=18) was comparable to that of untreated 
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mMLR cultures (2.66 ± 0.42%, N=18) and cultures containing unstimulated lymphocytes alone 
(1.60 ± 0.74%, N=6).  
 
Allodepleted T cells recognizing CMV, EBV, and Adenovirus antigens and viral-specific 
cells are enriched by stimulation 
Donor T cell responses to viral pathogens can protect the immunocompromised patient 
from early viral reactivation after SCT and support graft survival, engraftment, and immune 
reconstitution. Therefore, successful SD should preserve donor-derived viral-specific memory T 
cells. 
Allodepleted cultures generated from three donors were tested for recognition of peptide 
libraries for CMV antigens pp65 and IE-1, EBV antigens BZLF1 and EBNA1, and adenovirus 
antigen AD5 (Fig. 5a). Viral peptide recognition measured by IFN-γ production varied between 
donors. Antigen specific T cell responses to all viruses were retained and in 11/15 instances 
antigen-specific T cell frequencies were increased after adenosine-mediated allodepletion. 
Transfer of ex vivo expanded viral-specific T cells is a promising strategy to improve 
immune reconstitution after stem cell transplant made increasingly accessible by recent 
innovations in cell culture expansion.17 Since viral-specific T cells were preserved after 
adenosine treatment, our approach serves as a useful platform for expanding viral-specific T cells 
free of the risk of GVHD for adoptive transfer. To test this, cultures depleted with adenosine 
were washed and stimulated twice at weekly intervals with autologous DC pulsed with pp65 and 
IE-1 peptides. One week after the second stimulation, products were rested overnight and tested 
for reactivity against pp65, IE-1, or control WT1 as determined by the expression of TNF-α and 
IFN- 6 hour post peptide stimulation by flow cytometry. Enrichment of CMV-reacting cells, 
particularly polyfunctional T cells producing both TNF-α and IFN-, was achieved in three 
donors (Fig. 5b).  
 
T cells targeting leukemia-associated antigens (LAA), WT1 and PRAME can be generated 
from allodepleted products 
Graft lymphocyte-mediated anti-tumor immune responses are an essential function of the 
allograft in preventing relapse.18 T cells in particular can exhibit powerful toxicity against 
malignant cells if targeted to recognize tumor-identifying antigens. Tumor antigens such as 
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PRAME and WT1 are highly expressed in some leukemias, but precursor memory T cells 
recognizing these antigens are infrequent to nonexistent in healthy donors.  
To generate LAA-specific cells, lymphocytes allodepleted against mismatched DCs with 
adenosine were stimulated twice at weekly intervals with autologous DCs transduced to express 
PRAME or WT1 peptide. Polyfunctional recognition of PRAME and WT1 antigens was 
achieved in CD4+ and CD8+ T cell subsets of 3 donors (Figs. 6a,b), establishing the feasibility of 
generating tumor-targeted T cells from allodepleted cultures for adoptive immunotherapy where 
appropriate. 
  
Adenosine-mediated selective depletion is successful in haploidentical and matched sibling 
donor-recipient pairs  
SD was performed in haploidentical and matched sibling mMLR to verify the feasibility 
of this method in clinically relevant pairings.  Recipient DC stimulators were generated from 
pre-transplant patient PBMCs and cocultured separately with haploidentical and matched sibling 
donor PBMC responder cells. Adenosine treatments were the same for matched and mismatched 
donors. On day 7 post-mMLR, cells persisting in the cultures were labeled with CFSE and the 
selectivity of allodepletion was assessed by challenging cultures against a panel of stimulators in 
a 5 day proliferation assay as previously described. To reveal possible minor alloreactive cell 
populations, adenosine depleted cultures were compared to control cultures of unmanipulated 
mMLR. In three experiments, SD with adenosine reduced alloreactivity below that of untreated 
controls in both haploidentical and matched sibling mMLR (Fig. 7). Statistical analysis revealed 
that in the haploidentical setting, proliferation of the ‘donor’ allodepleted product against 
‘recipient’ APCs was significantly decreased compared to undepleted controls (*, P=0.011) 
while proliferation against 3rd party APCs was not significantly affected (ns, P=0.073). In the 
matched sibling setting, statistics revealed no significant differences between allodepleted 
cultures and controls, which is likely due to the low initial alloreactivity of Donor 2 against the 
matched sibling recipient. Further studies and in vivo models may provide a clearer case for 
employing this strategy in matched sibling transplants.  
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Discussion 
 
In this study we show that pharmacological concentrations of adenosine can selectively 
deplete alloreactive T cells responding to HLA-matched or mismatched APCs. This method 
exploits naturally tolerogenic functions of purine signaling to selectively eliminate activated T 
cells. Adenosine is produced physiologically by the metabolism of extracellular ATP released in 
response to cell injury, lysis, inflammation, or hypoxia.13 Conversion of ATP to AMP and then 
adenosine by the sequential action of ectonucleotidases CD39 and CD73 results in accumulation 
of adenosine in the extracellular space where the purine interacts with a family of cell surface G-
protein coupled adenosine receptors (A1, A2A, A2B, A3) inducing a concentration-dependent 
response13,15,19 Endogenous adenosine accumulation is implicated in the promotion of tumor 
metastasis and neoplastic expansion by local immunosuppression, reduction of inflammation, 
and protection against immune-mediated damage.13,14 In particular, adenosine signaling through 
the A2A receptor has been shown to disable NK and CTL cytotoxic functions and suppress the 
proliferation of activated T cells while additionally promoting tolerogenic DC 
differentiation.14,15,20 The mechanism of adenosine-mediated toxicity is thought to result from 
substantial accumulation of cytosolic cyclic AMP (cAMP), leading to DNA fragmentation and 
apoptosis.21,22 Our results confirm that at pharmacological doses adenosine is cytotoxic to 
activated T cells. The specific effects of pharmacological doses of adenosine on activated 
lymphocytes are not well understood. Extracellular adenosine is regulated by adenosine 
deaminase (ADA, CD26), which converts adenosine into inosine. ADA deficiency results in 
lymphopenia and severe combined immunodeficiency (SCID) highlighting the integral role of 
adenosine signaling in regulation of lymphocyte differentiation, survival and immune function, 
and homeostasis.20 It is worth noting that several artificial adenosine receptor ligands which 
might further boost adenosine-mediated SD have been synthesized and are available 
commercially.23 
We hypothesized that the immunosuppressive properties of adenosine might be harnessed 
to selectively deplete alloreacting cells from SCT in order to create GVHD-free cell products, 
particularly in haplo SCT where robust methods to prevent GVHD are needed. Here we 
demonstrated that adenosine blocked both the initiation of the alloresponse and also prevented 
subsequent proliferation of alloreactive T cells (Figs. 1a,b) in dose and time dependent manner. 
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Effective depletion of alloreactive cells was achieved by treating the cultures with 2mM 
adenosine on days 1, 2 and 5 of coculture. This method also depleted lymphocytes stimulated 
with anti-CD3/CD28 beads, demonstrating that adenosine is toxic to activated T cells at 
millimolar concentrations (Fig. 1c). The abrogation of alloresponse was maintained upon re-
challenge of depleted cultures against the original stimulator DCs (Fig. 2). The finding that the 
allodepleted lymphocytes do not proliferate upon secondary stimulation with the same 
stimulators in the absence of adenosine suggests that the alloreactive T cells are truly depleted 
from the culture. Interestingly, the response against 3rd party stimulators, though still present and 
robust, was significantly decreased in adenosine depleted cultures. This result may either reflect 
depletion of T cells reactive against shared minor antigens or depletion of some non alloreactive 
cells. Adenosine-treated cell cultures displayed unchanged proportions of naïve, CM, EM and 
effector T cells, indicating that only actively triggered memory (CM and EM) cells were targeted 
while in untreated allo-MLR cultures accumulation of memory T cells was observed. To ensure 
that cell populations desirable for transplant were retained, we further investigated the 
lymphocyte and T cell subsets persisting after depletion, particularly Tregs, virus recognizing T 
cells, and leukemia recognizing T cells. 
Phenotypic analysis revealed that while removing alloreactive T cells, adenosine 
preserved B and NK cells as well as naïve and memory T cell repertoires (Fig. 3). Memory T 
cells provide important immune competence against a variety of infectious agents including 
DNA viruses such as CMV, which complicate post-transplant outcome. Effective SD must retain 
these cells to prevent reactivation and opportunistic infection. We therefore tested the SD 
product for CMV, EBV, and AD5 reactivity. In three independent experiments we observed that 
allodepleted cultures maintained or sometimes enriched these viral-specific T cells. Using CMV 
as a model, we also showed that these peptide-recognizing cells can be expanded ex vivo through 
antigen-specific stimulation and exhibit the properties of adoptively transferred T cells used to 
control CMV after stem cell transplantation (Fig. 4).24 
It has been shown that donor T cells recognizing leukemia antigens are implicated in the 
GVL response, which is in part responsible for relapse-free survival after SCT.18 Particular 
antigens of interest are WT1 and PRAME, both of which are overexpressed in acute leukemias.25 
We therefore explored the ability of SD cultures to generate T cell responses to these antigens. 
Using autologous DCs transduced with lentiviral vectors to express and present naturally 
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processed epitopes of the target antigens, we showed in 3 experiments that CD4+ and CD8+ T 
cells specifically recognizing WT1 and PRAME can be elicited from SD cell products (Fig. 6). 
This result suggests that cultures depleted of alloreactive cells with adenosine could safely be 
used for adoptive transfer contributing to immune surveillance and protection against relapse 
while avoiding GVHD. 
Our findings indicate that adenosine SD preserves important immune responses which 
can determine SCT outcome. Furthermore technologies are being developed to generate antigen 
specific T cells to treat or prevent viral reactivation24,26 and leukemia relapse after SCT.27,28 Such 
cell products may still retain harmful alloreactivity, particularly in the haplo setting. Our data 
suggests that preemptive use of adenosine to deplete alloreactive cells could improve the quality 
and purity of such products.   
In this study we employed mature DC as stimulator APCs for their high expression of 
MHC and co-stimulatory molecules. DC proved highly effective stimulators, to the point of 
inducing background proliferation in autologous controls (Figs. 2,7). In designing selectively 
depleted SCT for hematopoietic malignancy, the choice of stimulator cell would determine the 
degree of antigenic overlap between the stimulator and the malignancy. In both HLA matched 
and mismatched settings, T cell recognition of minor histocompatibility antigens contributes to 
both GVHD and GVL.29 Thus, employing an APC sharing lineage with a patient’s specific tumor 
may unfavorably deplete donor T cells recognizing minor antigens identifying the tumor, 
reducing the GVL response. Selective depletion has been achieved with a variety of stimulator 
types such as unmanipulated PBMCs,30 ex vivo expanded CD8+ T lymphocytes,31 and EBV-
transformed B lymphoblastoid cell lines (EBV-LCL).32 Further work is required to identify the 
best APC for specific situations. 
The concept of using SD to reduce GVHD and maintain GVL is not new. Clinical studies 
employing anti-CD25 conjugated immunotoxin to eliminate CD25-expressing alloactivated T 
cells in ex vivo mMLR have been conducted previously in both haploidentical and matched 
sibling transplants.32,33 The studies in haploidentical transplants found that infusion of SD donor 
lymphocytes significantly aided immune reconstitution,32 but persisting GVHD was observed in 
matched sibling transplants.33 Further studies revealed that donor CD4+CD25+FOXP3+ Tregs 
significantly contributed to protection against acute GVHD in these transplants.6 Our 
experiments show that SD with adenosine spares these critical Tregs, highlighting the potential 
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for GVHD protection by this approach. Subsequent clinical studies adopted a photo depletion 
technique which targeted alloactivated cells in mMLR by their reduced ability to efflux a 
photosensitizing TH9402-based dye.31,34 While photo depletion exhibited positive results in 
haploidentical transplant,34,35 off-target depletion of CD4+ CM T cells in matched sibling 
transplants was associated with increased rate of infection and transplant related mortality.10 We 
have shown that adenosine specifically targets alloactivated T cells in mMLR and does not 
significantly deplete resting memory T cells. Importantly, using adenosine we achieved SD in 
both haploidentical and matched sibling mMLR (Fig. 7). In the matched sibling setting, we 
observed significant reduction in allo-responses between some two out of three donor/recipient 
pairs, while the initial alloreactivity was very low in one case. Further studies and in vivo models 
may provide a clearer case for employing this strategy in matched sibling transplants.  
 
 In conclusion, adenosine-based SD represents a readily applicable, inexpensive and 
robust approach to the persisting problem of refining the T cell content of the allograft to 
optimize SCT outcome for both HLA matched and mismatched donor-recipient pairs. The 
protocol is scalable and all reagents are GMP compliable.  
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Materials & Methods 
 
Cell culture  
Elutriated monocytes and lymphocytes were prepared from healthy donors, aged 20–80 years, 
from the Department of Transfusion Medicine at the National Institutes of Health. Recipient 
leukapheresis (LP) products were obtained from patients with acute myeloblastic leukemia 
(AML) in remission 20-30 days prior to transplantation. Responder (donor) LP products were 
obtained from HLA mismatched donors, matched sibling donors, and haploidentical parents or 
siblings of the corresponding recipient patients. Monocytes were immunomagnetically purified 
from PBMC by CD14 positive selection (Stemcell Technologies, Vancouver, BC, Canada). 
Dendritic cells (DC) were generated from elutriated or magnetically purified monocytes as 
described in the supplementary methods. HLA typing of the matched and haplodentical donor-
recipients is indicated in corresponding data figures. All participants in this study provided 
written informed consent. Ethical approval was granted by the NHLBI Institutional Review 
Board for all blood-product acquisitions in accordance with the declaration of Helsinki. Culture 
media composed of a 50:50 mix of AIM V and RPMI 1640 media supplemented with 100 U/mL 
penicillin, and 100 µg/mL streptomycin (Invitrogen, Carlsbad, CA), 5% heat-inactivated normal 
AB serum (Gemini Bio-Product, Woodland, CA) was used for culturing the cells. 
 
Ex vivo depletion of alloreactive donor cells 
GMP grade adenosine injection was obtained from Fresenius Kabi USA formulated as an 11mM 
solution (3mg/mL) in normal saline. Recipient DC stimulators were cocultured with or without 
mismatched, matched, or haploidentical sibling donor lymphocytes at a 1:10 ratio in 24 well 
plates for 7 to 10 days. Half of each culture was treated with different concentrations of 
adenosine on days 1, 2, and 5 of coculture (or as indicated in the figure legends) to deplete 
alloreactive cells. Control cultures were fed concurrently with an equal volume of normal saline. 
Two days after the final adenosine treatment, cells from allodepleted and untreated control 
cultures were sampled for phenotypic analysis. Remaining cells were rested for 16 to 24 hours 
and subjected to proliferation assay in secondary mMLR, after which, viability and phenotype 
were assessed by flow cytometry. Detailed methods and reagents used for flow cytometry 
analysis are provided in the supplementary methods.  
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Proliferation assay 
Adenosine treated and control cell cultures were harvested and labeled with CFSE as described 
in the supplementary methods. Cells were then co-cultured with a panel of targets in 96 well 
plates for 5 days after which proliferation by CFSE dye dilution was measured by flow 
cytometry. The targets tested were: dendritic cells (DC) autologous to responder T cells to 
measure background proliferation, stimulator DC to measure alloreacting cells, and a mix of DC 
from 3 unrelated donors to measure response to de novo antigens. Stimulation of T cells with 
anti-CD3/CD28 Beads (Dynabeads® Human T-Activator CD3/CD28; Invitrogen) was used to 
measure maximum proliferative capacity. Responder-DC cocultures were established at a 10:1 
ratio and responder-bead cocultures were established at a 3:1 ratio. Cultured cells were assessed 
for viability and phenotype by flow cytometry. In some experiments, lymphocytes from 3 
healthy donors were stimulated with anti-CD3/CD28 beads and treated with 2mM adenosine on 
days 1, 2, and 5 or left untreated. Two days after the final treatment, cells in culture were 
assessed for viability by flow cytometry to determine the cytotoxicity of adenosine to 
lymphocytes. Detailed methods and reagents used to analyze the cell viability and phenotype by 
flow cytometry were provided in the supplementary methods. 
 
Testing for preexisting antiviral activity 
Pepmix peptide pools composed of a 15-mer peptides spanning the entire protein sequence and 
overlapping by 11 amino acids for pp65, IE-1, EBNA1, BZLF1, and AD5 antigens were 
acquired from JPT (Berlin, Germany). Cultures to be tested were rested overnight and then 
individually stimulated with the indicated peptides in 96 well plates according to manufacturer’s 
instructions. One hour post peptide stimulation at 37˚C, protein transport inhibitors Brefeldin A 
and Monensin (BD Biosciences) were added. Cultures were incubated for additional 5 hours and 
then stained with fluorescent labeled antibodies against T cell surface markers and intracellular 
cytokines and analyzed by flow cytometry to determine their reactivity and antigen-specificity. 
 
Ex vivo expansion of CMV-specific T cells 
To expand effector T cells with specificity against CMV antigens, lymphocytes allodepleted with 
adenosine were primed twice at weekly interval with mature autologous DC pulsed with CMV 
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pp65 and IE-1 pepmix (JPT) at a responder to stimulator ratio of 5:1. Cultures received IL-7 (10 
ng/mL) and IL-15 (10 ng/mL) during first priming and IL-2 (10 IU) in addition to IL-7 and IL-15 
during second priming step. Resulting effector T cell cultures were tested for reactivity against 
CMV pp65 and IE-1 antigens as described above. 
 
Ex vivo generation of leukemia associated antigen-specific T cells 
To generate and expand leukemia associated antigen PRAME and WT1 specific effector T cells 
we used autologous DC as APC engineered with lentivirus to express these antigens as described 
in the supplementary methods. Cells were harvested from adenosine treated mMLR cultures on 
day 7 and primed twice at weekly interval with indicated target antigen-transduced mature 
autologous DC at a responder to stimulator ratio of 5:1. Cultures were expanded in the presence 
of cytokines as described for CMV-specific T cells. Resulting effector T cell cultures were tested 
for reactivity against autologous DC pulsed with peptide libraries derived from corresponding 
target antigen or irrelevant control antigen. 
 
Statistical analysis 
Graphs were plotted using Graphpad Software (La Jolla, CA). Data are presented as mean, with 
standard error bars where appropriate. Statistical analysis was performed either using paired or 
unpaired Student t test where P ≤ 0.05 was considered statistically significant (*, P ≤ 0.05; **, 
P ≤ 0.01; ***, P ≤ 0.001). 
 
 
 
 
 
 
 
WHITEHILL GD et al  Selective T cell depletion with adenosine 
17 
 
Acknowledgments 
This research was supported by the Intramural Research Program of the National Institutes of 
Health at the NHLBI. The authors thank Nancy Hensel and Fariba Chinian (Hematology Branch, 
NHLBI, NIH, Bethesda, MD) for their technical assistance. 
Conflict-of-interest disclosure 
 The authors declare no competing financial interests. 
Authorship 
Contribution: D.C. conceived, designed, and supervised the study, D.C. and  G.D.W. planned 
and executed the experiments, interpreted the data, and wrote the manuscript; S.A. and B.M. 
assisted with experimental design and commented on the manuscript; K.K. assisted with flow 
cytometry; P.M. commented on of the manuscript; A.J.B. supervised the study and assisted in the 
manuscript writing. All authors approved the final manuscript. 
 
 
 
 
 
 
 
 
 
 
 
 
WHITEHILL GD et al  Selective T cell depletion with adenosine 
18 
 
References: 
1. Martelli, MF, Di Ianni, M, Ruggeri, L, Falzetti, F, Carotti, A, Terenzi, A, et al. (2014). 
HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive 
immunotherapy prevents acute leukemia relapse. Blood 124: 638-644. 
2. Huang, XJ, Liu, DH, Liu, KY, Xu, LP, Chen, H, Han, W, et al. (2009). Treatment of 
acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone 
marrow transplantation. Biology of blood and marrow transplantation : journal of the 
American Society for Blood and Marrow Transplantation 15: 257-265. 
3. Kanakry, CG, Tsai, HL, Bolanos-Meade, J, Smith, BD, Gojo, I, Kanakry, JA, et al. 
(2014). Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide 
after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood 124: 3817-
3827. 
4. Luznik, L, O'Donnell, PV, Symons, HJ, Chen, AR, Leffell, MS, Zahurak, M, et al. 
(2008). HLA-haploidentical bone marrow transplantation for hematologic malignancies 
using nonmyeloablative conditioning and high-dose, posttransplantation 
cyclophosphamide. Biology of blood and marrow transplantation : journal of the 
American Society for Blood and Marrow Transplantation 14: 641-650. 
5. Ganguly, S, Ross, DB, Panoskaltsis-Mortari, A, Kanakry, CG, Blazar, BR, Levy, RB, et 
al. (2014). Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation 
cyclophosphamide-mediated protection against GVHD in mice. Blood 124: 2131-2141. 
6. Mielke, S, Rezvani, K, Savani, BN, Nunes, R, Yong, AS, Schindler, J, et al. (2007). 
Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted 
allotransplantation in elderly patients and association with acute graft-versus-host 
disease. Blood 110: 1689-1697. 
7. Rezvani, K, Mielke, S, Ahmadzadeh, M, Kilical, Y, Savani, BN, Zeilah, J, et al. (2006). 
High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk 
of GVHD following HLA-matched allogeneic SCT. Blood 108: 1291-1297. 
8. Mielke, S, Solomon, SR, and Barrett, AJ (2005). Selective depletion strategies in 
allogeneic stem cell transplantation. Cytotherapy 7: 109-115. 
9. Bastien, JP, Roy, J, and Roy, DC (2012). Selective T-cell depletion for haplotype-
mismatched allogeneic stem cell transplantation. Seminars in oncology 39: 674-682. 
10. McIver, ZA, Melenhorst, JJ, Grim, A, Naguib, N, Weber, G, Fellowes, V, et al. (2011). 
Immune reconstitution in recipients of photodepleted HLA-identical sibling donor stem 
cell transplantations: T cell subset frequencies predict outcome. Biology of blood and 
marrow transplantation : journal of the American Society for Blood and Marrow 
Transplantation 17: 1846-1854. 
11. Mielke, S, McIver, ZA, Shenoy, A, Fellowes, V, Khuu, H, Stroncek, DF, et al. (2011). 
Selectively T cell-depleted allografts from HLA-matched sibling donors followed by 
low-dose posttransplantation immunosuppression to improve transplantation outcome in 
patients with hematologic malignancies. Biology of blood and marrow transplantation : 
journal of the American Society for Blood and Marrow Transplantation 17: 1855-1861. 
12. Roy, D-C, Lachance, S, Roy, J, Walker, I, Maertens, J, Cohen, S, et al. (2015). Donor 
Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related 
Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML 
WHITEHILL GD et al  Selective T cell depletion with adenosine 
19 
 
and ALL, Using an Immunosuppressant-Free Transplant Regimen. Blood 126: 4391-
4391. 
13. Antonioli, L, Blandizzi, C, Pacher, P, and Hasko, G (2013). Immunity, inflammation and 
cancer: a leading role for adenosine. Nat Rev Cancer 13: 842-857. 
14. Young, A, Mittal, D, Stagg, J, and Smyth, MJ (2014). Targeting cancer-derived 
adenosine: new therapeutic approaches. Cancer discovery 4: 879-888. 
15. Zarek, PE, and Powell, JD (2007). Adenosine and anergy. Autoimmunity 40: 425-432. 
16. Melenhorst, JJ, Scheinberg, P, Williams, A, Ambrozak, DR, Keyvanfar, K, Smith, M, et 
al. (2011). Alloreactivity across HLA barriers is mediated by both naive and antigen-
experienced T cells. Biology of blood and marrow transplantation : journal of the 
American Society for Blood and Marrow Transplantation 17: 800-809. 
17. Barrett, AJ, and Bollard, CM (2015). The coming of age of adoptive T-cell therapy for 
viral infection after stem cell transplantation. Annals of translational medicine 3: 62. 
18. Barrett, AJ (2008). Understanding and harnessing the graft-versus-leukaemia effect. 
British journal of haematology 142: 877-888. 
19. Hasko, G, Linden, J, Cronstein, B, and Pacher, P (2008). Adenosine receptors: 
therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7: 759-
770. 
20. Huang, S, Apasov, S, Koshiba, M, and Sitkovsky, M (1997). Role of A2a extracellular 
adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell 
activation and expansion. Blood 90: 1600-1610. 
21. Kizaki, H, Suzuki, K, Tadakuma, T, and Ishimura, Y (1990). Adenosine receptor-
mediated accumulation of cyclic AMP-induced T-lymphocyte death through 
internucleosomal DNA cleavage. The Journal of biological chemistry 265: 5280-5284. 
22. McConkey, DJ, Orrenius, S, and Jondal, M (1990). Agents that elevate cAMP stimulate 
DNA fragmentation in thymocytes. Journal of immunology (Baltimore, Md : 1950) 145: 
1227-1230. 
23. Klotz, KN (2000). Adenosine receptors and their ligands. Naunyn-Schmiedeberg's 
archives of pharmacology 362: 382-391. 
24. Leen, AM, Bollard, CM, Mendizabal, AM, Shpall, EJ, Szabolcs, P, Antin, JH, et al. 
(2013). Multicenter study of banked third-party virus-specific T cells to treat severe viral 
infections after hematopoietic stem cell transplantation. Blood 121: 5113-5123. 
25. Goswami, M, Hensel, N, Smith, BD, Prince, GT, Qin, L, Levitsky, HI, et al. (2014). 
Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy 
tissues. Leukemia 28: 1167-1170. 
26. Papadopoulou, A, Gerdemann, U, Katari, UL, Tzannou, I, Liu, H, Martinez, C, et al. 
(2014). Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and 
HHV6 infections after HSCT. Science translational medicine 6: 242ra283. 
27. Weber, G, Caruana, I, Rouce, RH, Barrett, AJ, Gerdemann, U, Leen, AM, et al. (2013). 
Generation of tumor antigen-specific T cell lines from pediatric patients with acute 
lymphoblastic leukemia--implications for immunotherapy. Clinical cancer research : an 
official journal of the American Association for Cancer Research 19: 5079-5091. 
28. Weber, G, Gerdemann, U, Caruana, I, Savoldo, B, Hensel, NF, Rabin, KR, et al. (2013). 
Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-
leukemia effect after allogeneic stem cell transplant. Leukemia 27: 1538-1547. 
WHITEHILL GD et al  Selective T cell depletion with adenosine 
20 
 
29. Spierings, E, Kim, YH, Hendriks, M, Borst, E, Sergeant, R, Canossi, A, et al. (2013). 
Multicenter analyses demonstrate significant clinical effects of minor histocompatibility 
antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic 
stem cell transplantation. Biology of blood and marrow transplantation : journal of the 
American Society for Blood and Marrow Transplantation 19: 1244-1253. 
30. Andre-Schmutz, I, Le Deist, F, Hacein-Bey-Abina, S, Vitetta, E, Schindler, J, Chedeville, 
G, et al. (2002). Immune reconstitution without graft-versus-host disease after 
haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet (London, England) 
360: 130-137. 
31. Mielke, S, Nunes, R, Rezvani, K, Fellowes, VS, Venne, A, Solomon, SR, et al. (2008). A 
clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and 
matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells 
and a TH9402-based photodepletion technique. Blood 111: 4392-4402. 
32. Amrolia, PJ, Muccioli-Casadei, G, Huls, H, Adams, S, Durett, A, Gee, A, et al. (2006). 
Adoptive immunotherapy with allodepleted donor T-cells improves immune 
reconstitution after haploidentical stem cell transplantation. Blood 108: 1797-1808. 
33. Solomon, SR, Mielke, S, Savani, BN, Montero, A, Wisch, L, Childs, R, et al. (2005). 
Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the 
severity of graft-versus-host disease in older patients undergoing matched sibling donor 
stem cell transplantation. Blood 106: 1123-1129. 
34. Roy, DC, Lachance, S, Kiss, T, Cohen, S, Busque, L, Fish, D, et al. (2009). 
Haploidentical Stem Cell Transplantation: High Doses of Alloreactive-T Cell Depleted 
Donor Lymphocytes Administered Post-Transplant Decrease Infections and Improve 
Survival without Causing Severe Gvhd. Blood 114: 212-212. 
35. Roy, DC, Guerin, M, Boumedine, RS, Lachance, S, Cohen, S, Sauvageau, G, et al. 
(2011). Reduction in Incidence of Severe Infections by Transplantation of High Doses of 
Haploidentical T Cells Selectively Depleted of Alloreactive Units. Blood 118: 1301-
1301. 
 
 
 
 
 
 
 
 
 
 
WHITEHILL GD et al  Selective T cell depletion with adenosine 
21 
 
Figure Legends 
Figure 1: Millimolar adenosine suppresses T cell alloactivation and proliferation. (a) FACS 
analysis showing percent CD25+ T cells in culture after stimulation of healthy donor 
lymphocytes with HLA-mismatched recipient DC over 8 days in the presence or absence of 
various doses of adenosine on days 1, 2, and 5 after establishing cocultures. (b) CFSE labeled 
donor lymphocytes were cocultured with HLA-mismatched recipient DCs for 10 days. Cultures 
were treated with 2mM adenosine on day 2 or 5 only, or days 1, 2, and 5 after establishing 
mMLR. Two days after the final treatment, CFSE dye dilution in T cells was determined as a 
measure of cell proliferation by flow cytometry. Results shown in Figure 1A and 1B are the 
mean of 6 HLA-mismatched donor-recipient pairs. (c) Lymphocytes from 3 healthy donors were 
stimulated with anti-CD3/CD28 beads and treated with 2mM adenosine on days 1, 2, and 5 
(+Ado) or not treated (No Ado). Two days after the final treatment cultures were stained with 
Vivid and viability was determined by flow cytometry. Results shown are representative of 3 
donors.  
Figure 2: Adenosine selectively depletes alloreactive T cells in HLA-mismatch mMLR 
while retaining activity against 3rd Party APCs. Adenosine allodepleted lymphocytes (Ado) 
and unmanipulated lymphocytes cultured for 7 days (NT Ctrl) were stained with CFSE and 
tested for proliferative response against a panel of stimulators in secondary mMLR. CFSE dye 
dilution in T cells was determined by flow cytometry as a measure of proliferation. (a) 
Representative data from one donor depicting proliferation of freshly thawed lymphocytes (Pre-
Depletion) and Ado depleted lymphocytes (Post-Depletion) challenged against stimulator DCs 
for 5 days. (b) Overlayed histograms of CFSE dilution profile for representative donor shows 
abrogation of response against stimulator DCs. (c) Pooled data from 5 responder-recipient pairs, 
background proliferation against autologous DCs subtracted from presented values. 
Figure 3: Allodepletion with adenosine preserves lymphocyte and T cell subsets. Primary 
mMLR cultures were established using 12 distinct donor lymphocyte and mismatched recipient 
DC pairs. Cultures were treated with adenosine on day 1, 2, and 5 (Ado MLR, N=12) or left 
untreated (NT MLR, N=12). Responder lymphocytes were cultured alone (NT Ctrl, N=6). After 
7 days, the samples were harvested, washed, and phenotype was analyzed by flow cytometry. 
Lymphocyte subsets were identified as B cells (CD19+CD3-), total NK cells (CD56+CD19-), 
NKT cells (CD3+ CD56+), total T cells (CD3+CD19-CD56-), CD4+ T cells (CD3+CD4+), or 
CD8+ T cells (CD3+CD8+). (a, left) Total T, CD4+ Th, and CD8+ CTL frequencies. (a, right) 
Total NK, NKT, and B cell frequencies. (b) Gating strategy used to identify various T cell subset 
denominations. CD3+ T cells were classified as naïve (CCR7+CD45RO-), central memory (CM, 
CCR7+CD45RO+), effector memory (EM, CCR7-CD45RO+), or terminal effector (EMRA, 
CCR7-CD45RO-). (c, d) Pooled data from one experiment showing the frequency and 
distribution of various T cell subsets in adenosine treated or untreated mMLR cultures (N=12) or 
responder lymphocyte alone control cultures (N=6).  
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Figure 4: Tregs are not depleted by adenosine. Responder lymphocytes were cultured with no 
stimulation (NT Ctrl), in mMLR against mismatch stimulator DCs with adenosine treatment 
(Ado), or in mMLR without treatment (NT MLR). After seven days, the cultures were analyzed 
to determine the frequency of CD25+FOXP3+ Tregs within CD3+CD4+ T by flow cytometry. (a) 
Representative dot plot analysis of sample from one donor showing the gating strategy used to 
determine the CD3+CD4+CD25+FOXP3+ Tregs. (b) Frequency of CD3+CD4+ CD25+FOXP3+ 
Tregs in NT Ctrl (N=1), Ado (N=3), and NT mMLR (N=3) cultures for six donors. Each donor 
was depleted or cultured in mMLR against 3 distinct recipients. 
Figure 5: T cells recognizing viral peptides persist after depletion and can be expanded 
through stimulation with peptide-pulsed APCs. Recognition of CMV (pp65, IE-1), EBV 
(EBNA1, BZLF1), and adenovirus (AD5) antigens tested by 6 hour peptide stimulation; 
intracellular expression of IFN- and TNF-α were measured by flow cytometry. (a) 
Lymphocytes from 3 CMV seropositive donors were depleted against allogeneic DCs with 
adenosine (Ado), cultured for an equal period with no stimulation (NT Day 7), or thawed fresh 
(NT Day 0) and tested against panel of viral peptide libraries. The background of IFN-+ cells 
against irrelevant peptide is subtracted from raw data in the presented values. (b) CMV-specific 
cells expanded from adenosine depleted cultures through two rounds of peptide stimulation show 
polyfunctional response against pp65 and IE-1 peptides. 
Figure 6: Leukemia associated antigen specific T cells were generated from allodepleted 
cultures. Adenosine depleted lymphocytes from 6 mismatched donor-recipient pairs were 
stimulated twice at weekly interval with autologous DCs transduced with a lentiviral vector 
expressing PRAME or WT1 to generate and enrich antigen-recognizing T cells. Antigen 
specificity was tested against DCs transduced with the cognate antigen PRAME or WT1, or 
irrelevant control antigen in a 6 hour coculture assay followed by intracellular flow cytometry for 
cytokine production analysis. Production of IFN- and TNF-α in recognition of cognate antigen 
over background control in CD4+ and CD8+ T cell subsets is presented for (a) PRAME-specific 
cultures and (b) WT1-specific cultures from 3 donor-recipient pairs. 
Figure 7: Adenosine-mediated allodepletion was highly effective in haploidentical and 
matched sibling mMLR. SD with adenosine was performed in mMLR coculture of ‘donor’ 
haploidentical (a) and matched sibling (b) PBMCs with ‘recipient’ DCs in three experiments. 
HLA serology of donors and recipients for each experiment are reported. Reactivity of 
allodepleted product (Ado) and untreated mMLR control (Ctrl) against donor DCs, recipient 
DCs, a mix of unrelated 3rd party DCs, and anti-CD3/CD28 beads is presented. The reported % 
reactivity values reflect percentage of CFSE low T cells minus background proliferation of 
unstimulated cultures. 
 







